Form 4 for HAE HAEMONETICS CORP
Accepted 2025-05-20 00:00:00 ET · period of report 2025-05-16 · accession 0001127602-25-015052 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-05-20 | 2025-05-16 | HAE | Simon, Christopher | Pres, CEO, Dir | A - Grant | — | +21.4K | 335.1K | +7% | — |
| D | 2025-05-20 | 2025-05-16 | HAE | Simon, Christopher | Pres, CEO, Dir | A - Grant | $0.00 | +46.3K | 46.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-16 | A | A | 21,405 | — | 335,112 | D | — | — | (F1) The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. (F2) Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. (F3) This number includes unvested RSUs previously reported. |
| 2 | Derivative | Non-qualified Stock Option (Right to Buy) | 2025-05-16 | A | A | 46,342 | $0.00 | 46,342 | D | $70.31 · — to 2032-05-16 | 46,342 Common Stock | (F4) Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. |